Next year, Rosstat reports , a monthly monitoring system for drug prices for COVID-19 patients will be launched. The monitoring will concern azithromycin, ceftriaxone, oseltamivir (nomides), apixaban (eliquis), vitamin D3. It should be noted that Rosstat monthly monitors prices for 43 drugs, 19 of which are included in the list of vital drugs (Vital drugs). Five new drugs for which prices will be tracked from early 2021 are also on this list.
This decision was made due to the fact that drug prices since the beginning of the year have been growing at a rate more than double the overall inflation rate (over 11 months they increased by 9% with an average increase in consumer prices by 4.1%). For example, since the beginning of the year to December 14, Linex has risen in price by 35.6%, analgin - by 21.1%.
Meanwhile, an International Consortium led by the Cambridge Medical Research Council (MRC) has launched an open platform to accelerate drug discovery for COVID-19.
All users of the platform will have access to information on genetic variations of host cell proteins (host proteins) specific to the proteins of the SARS-CoV-2 coronavirus. All information has been collected by MRC. So, to date, common genetic variations of 179 proteins are known, which are associated with the development of severe forms of coronavirus infection.
According to representatives of the MRC, some host proteins may be targets for targeted therapy for coronavirus infection, which inhibits the entry of the virus into the cell and its reproduction